Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MRUS
stocks logo

MRUS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
8.63M
-5.57%
-1.060
+116.27%
9.08M
-65.73%
-1.288
-7.99%
8.85M
+0.25%
-1.232
-44.76%
Estimates Revision
The market is revising Upward the revenue expectations for Merus N.V. (MRUS) for FY2025, with the revenue forecasts being adjusted by 5.83% over the past three months. During the same period, the stock price has changed by 42.61%.
Revenue Estimates for FY2025
Revise Upward
up Image
+5.83%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-6.47%
In Past 3 Month
Stock Price
Go Up
up Image
+42.61%
In Past 3 Month
Wall Street analysts forecast MRUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRUS is 97.71 USD with a low forecast of 92.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
Wall Street analysts forecast MRUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRUS is 97.71 USD with a low forecast of 92.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
14 Hold
0 Sell
Hold
Current: 96.220
sliders
Low
92.00
Averages
97.71
High
112.00
Current: 96.220
sliders
Low
92.00
Averages
97.71
High
112.00
Barclays
Overweight -> Equal Weight
downgrade
$112 -> $97
2025-09-30
Reason
Barclays
Price Target
$112 -> $97
2025-09-30
downgrade
Overweight -> Equal Weight
Reason
Barclays downgraded Merus (MRUS) to Equal Weight from Overweight with a price target of $97, down from $112, after the company agreed to be acquired by Genmab (GMAB) is an all-cash transaction valued at $8.0B, or $97 per share. The firm expects a timely deal closure and sees a low probability of another bidder.
BMO Capital
Evan Seigerman
Outperform -> Market Perform
downgrade
$110 -> $97
2025-09-30
Reason
BMO Capital
Evan Seigerman
Price Target
$110 -> $97
2025-09-30
downgrade
Outperform -> Market Perform
Reason
BMO Capital analyst Evan Seigerman downgraded Merus (MRUS) to Market Perform from Outperform with a price target of $97, down from $110, after the company agreed to be acquired by Genmab (GMAB) is an all-cash transaction valued at $8.0B, or $97 per share. The firm views the deal as a "significant positive" for shareholders.
UBS
Buy
to
Neutral
downgrade
$72 -> $97
2025-09-30
Reason
UBS
Price Target
$72 -> $97
2025-09-30
downgrade
Buy
to
Neutral
Reason
UBS downgraded Merus (MRUS) to Neutral from Buy with a price target of $97, up from $72, after the company agreed to be acquired by Genmab (GMAB) is an all-cash transaction valued at $8.0B, or $97 per share. The firm sees limited overlap with Genmab's existing pipeline.
LifeSci Capital
Charles Zhu
Outperform
to
Market Perform
downgrade
$97
2025-09-29
Reason
LifeSci Capital
Charles Zhu
Price Target
$97
2025-09-29
downgrade
Outperform
to
Market Perform
Reason
LifeSci Capital analyst Charles Zhu downgraded Merus (MRUS) to Market Perform from Outperform with a $97 price target after the company agreed to be acquired by Genmab (GMAB) is an all-cash transaction valued at $8.0B, or $97 per share
Needham
Ami Fadia
Buy -> Hold
downgrade
2025-09-29
Reason
Needham
Ami Fadia
Price Target
2025-09-29
downgrade
Buy -> Hold
Reason
Needham analyst Ami Fadia downgraded Merus to Hold from Buy without a price target after the company entered into an agreement pursuant to which Genmab (GMAB) will acquire all the shares of Merus for $97 per share in an all-cash transaction, representing a transaction value of $8B.
Wells Fargo
Eva Fortea Verdejo
Overweight -> Equal Weight
downgrade
$95 -> $97
2025-09-29
Reason
Wells Fargo
Eva Fortea Verdejo
Price Target
$95 -> $97
2025-09-29
downgrade
Overweight -> Equal Weight
Reason
Wells Fargo analyst Eva Fortea Verdejo downgraded Merus (MRUS) to Equal Weight from Overweight with a price target of $97, up from $95, after the company entered into an agreement pursuant to which Genmab (GMAB) will acquire all the shares of Merus for $97 per share in an all-cash transaction, representing a transaction value of $8B.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Merus NV (MRUS.O) is -20.28, compared to its 5-year average forward P/E of -10.70. For a more detailed relative valuation and DCF analysis to assess Merus NV 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-10.70
Current PE
-20.28
Overvalued PE
-6.98
Undervalued PE
-14.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.98
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-3.32
Undervalued EV/EBITDA
-10.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
50.97
Current PS
0.00
Overvalued PS
95.21
Undervalued PS
6.72
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

MRUS News & Events

Events Timeline

(ET)
2025-11-17
07:05:10
Merus and Halozyme Form Partnership and Licensing Deal for Petosemtamab
select
2025-10-24 (ET)
2025-10-24
10:38:35
Merus to Showcase Interim Findings on Petosemtamab at AACR-NCI-EORTC Conference
select
2025-10-14 (ET)
2025-10-14
12:12:36
Oppenheimer Optimistic About CytomX Following Merus Colon Cancer Results
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
12-04Globenewswire
Marius Pharmaceuticals CEO to Speak at FDA Expert Panel on Testosterone Therapy
  • Industry Milestone: Marius Pharmaceuticals CEO Shalin Shah will speak at the FDA Expert Panel on Testosterone Replacement Therapy for Men on December 10, 2025, marking a significant advancement in men's health and expected to enhance scientific discussions around testosterone therapy.
  • Regulatory Shift: The FDA will open a public docket to gather questions and data related to testosterone therapy, reflecting a commitment to reevaluating long-standing misconceptions and potentially impacting treatment options for millions of men.
  • Scientific Dialogue: The panel, hosted by Dr. Brian Christine, will feature Shah and other experts sharing insights on the scientific, clinical, and regulatory aspects of testosterone therapy, aiming to correct misconceptions and promote evidence-based treatment.
  • Live Participation: The event will be livestreamed from 1 PM to 3 PM ET, allowing public participation for those unable to attend in person, further enhancing Marius's influence and public awareness in the men's health sector.
[object Object]
Preview
7.0
11-22Globenewswire
Halper Sadeh LLC Urges EXAS, NVRI, MRUS Shareholders to Reach Out for Rights Consultation

  • Investigation of Companies: Halper Sadeh LLC is investigating Exact Sciences Corporation, Enviri Corporation, and Merus N.V. for potential violations of federal securities laws and breaches of fiduciary duties related to their respective sales.

  • Exact Sciences Sale: Exact Sciences is being sold to Abbott for $105.00 per share in cash, prompting an investigation into the transaction's fairness for shareholders.

  • Enviri Corporation Sale: Enviri's sale of Clean Earth to Veolia Environnement SA is expected to provide shareholders with cash consideration between $14.50 and $16.50 per share, which is also under scrutiny.

  • Legal Support for Shareholders: Halper Sadeh LLC offers free consultations to shareholders regarding their legal rights and options, emphasizing that they operate on a contingent fee basis, meaning no upfront legal fees are required.

[object Object]
Preview
7.5
11-17NASDAQ.COM
Merus Acquires License for Halozyme Therapeutics' ENHANZE Drug Delivery Technology

  • Collaboration Agreement: Merus N.V. has entered a global non-exclusive collaboration and license agreement with Halozyme Therapeutics for the ENHANZE drug delivery technology.

  • Product Development: The agreement allows Merus to develop and potentially commercialize subcutaneous administration of petosemtamab, which shows promise in treating various solid tumor cancers, particularly head and neck cancer.

  • Financial Terms: Merus will make an upfront payment to Halozyme and may incur future milestone payments based on commercial success, along with royalties on net sales of the product.

  • Market Update: As of November 14, Merus N.V. shares closed at $95.95, reflecting a slight decrease of 0.14% on the Nasdaq.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Merus NV (MRUS) stock price today?

The current price of MRUS is 96.22 USD — it has increased 0.1 % in the last trading day.

arrow icon

What is Merus NV (MRUS)'s business?

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

arrow icon

What is the price predicton of MRUS Stock?

Wall Street analysts forecast MRUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRUS is 97.71 USD with a low forecast of 92.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Merus NV (MRUS)'s revenue for the last quarter?

Merus NV revenue for the last quarter amounts to 12.15M USD, increased 3.21 % YoY.

arrow icon

What is Merus NV (MRUS)'s earnings per share (EPS) for the last quarter?

Merus NV. EPS for the last quarter amounts to -1.26 USD, decreased -13.70 % YoY.

arrow icon

What changes have occurred in the market's expectations for Merus NV (MRUS)'s fundamentals?

The market is revising Upward the revenue expectations for Merus N.V. (MRUS) for FY2025, with the revenue forecasts being adjusted by 5.83% over the past three months. During the same period, the stock price has changed by 42.61%.
arrow icon

How many employees does Merus NV (MRUS). have?

Merus NV (MRUS) has 260 emplpoyees as of December 05 2025.

arrow icon

What is Merus NV (MRUS) market cap?

Today MRUS has the market capitalization of 7.29B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free